Structural analysis of setmelanotide binding to MC4R variants in comparison to wild-type receptor
- PMID: 35931197
- DOI: 10.1016/j.lfs.2022.120857
Structural analysis of setmelanotide binding to MC4R variants in comparison to wild-type receptor
Abstract
Aims: Melanocortin 4 receptor (MC4R) has a well-established role in regulating appetite, food intake and energy homeostasis. Setmelanotide is an MC4R agonist currently approved for weight loss in obese adults and children with mutations in components of the leptin-melanocortin pathway. This study aims to compare structural and functional aspects of the physiological MC4R agonist α-melanocyte-stimulating hormone (α-MSH) with setmelanotide. We also aim to show the binding affinity of setmelanotide to known MC4R human missense mutations associated with obesity.
Main methods: AutoDock Vina was used in the structural analysis to calculate induced fit docking scores of ligand binding to MC4R wild type or the selected variants. HEK293-MC4R were utilized in the functional analysis of MC4R-actiavted pathways upon stimulating with α-MSH or setmelanotide.
Key findings: Our data shows that setmelanotide has a higher potency for cAMP formation and a weaker effect on ERK1/2 phosphorylation when compared to α-MSH indicating functional selectivity otherwise known as biased agonism. We also present structural data showing that setmelanotide has a higher binding affinity to MC4R compared to α-MSH. Lastly, we show that two loss-of-function and two gain-of-function MC4R variants change the conformation not only of the ligand binding pocket of the receptor but also of the peptide when bound to the receptor because the interaction network and the residues involved in the binding are altered.
Significance: Taken together, our study provides important insights into the diversity of MC4R signaling pathways which will facilitate the development of personalized anti-obesity drugs via refining MC4R agonists.
Keywords: Functional selectivity; MC4R; Molecular docking; Obesity; Setmelanotide.
Copyright © 2022. Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest The authors declare that there are no conflicts of interest.
Similar articles
-
MC4R Variants Modulate α-MSH and Setmelanotide Induced Cellular Signaling at Multiple Levels.J Clin Endocrinol Metab. 2024 Sep 16;109(10):2452-2466. doi: 10.1210/clinem/dgae210. J Clin Endocrinol Metab. 2024. PMID: 38567654 Free PMC article.
-
Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.Mol Metab. 2017 Oct;6(10):1321-1329. doi: 10.1016/j.molmet.2017.06.015. Epub 2017 Jul 8. Mol Metab. 2017. PMID: 29031731 Free PMC article. Clinical Trial.
-
Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach.ACS Chem Neurosci. 2019 Mar 20;10(3):1055-1065. doi: 10.1021/acschemneuro.8b00346. Epub 2018 Aug 13. ACS Chem Neurosci. 2019. PMID: 30048591 Free PMC article.
-
Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment.Trends Mol Med. 2019 Feb;25(2):136-148. doi: 10.1016/j.molmed.2018.12.002. Epub 2019 Jan 11. Trends Mol Med. 2019. PMID: 30642682 Review.
-
Melanocortin pathways: suppressed and stimulated melanocortin-4 receptor (MC4R).Physiol Res. 2020 Sep 30;69(Suppl 2):S245-S254. doi: 10.33549/physiolres.934512. Physiol Res. 2020. PMID: 33094623 Free PMC article. Review.
Cited by
-
G protein-coupled receptors and obesity.Front Endocrinol (Lausanne). 2023 Dec 14;14:1301017. doi: 10.3389/fendo.2023.1301017. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38161982 Free PMC article. Review.
-
Exploring the Frontier of Cyclic Dipeptides: A Bioinformatics Approach to Potential Therapeutic Applications in Schizophrenia.Int J Mol Sci. 2024 Oct 24;25(21):11421. doi: 10.3390/ijms252111421. Int J Mol Sci. 2024. PMID: 39518975 Free PMC article. Review.
-
MC4R Variants Modulate α-MSH and Setmelanotide Induced Cellular Signaling at Multiple Levels.J Clin Endocrinol Metab. 2024 Sep 16;109(10):2452-2466. doi: 10.1210/clinem/dgae210. J Clin Endocrinol Metab. 2024. PMID: 38567654 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous